Researchers Uncover a Secret of the Black Death

September 18, 2006

Yersinia pestis, the bacteria that causes plague, is a sneaky little intruder with a remarkable ability to evade the body’s immune system. Upon entering an organism, Y. pestis employs a variety of strategies to slip below the radar of the innate immune response—the body’s front line of defense against invading pathogens—and in many cases kills the host before its more specific antibacterial response can develop.

It is this stealth and virulence that has made plague one of the most feared diseases in human history, blamed for more than 200 million deaths. While human cases of plague in the United States are now rare, a few thousands worldwide are infected each year and with the potential of intentional misuse of Y. pestis, the efforts to develop better treatments and a vaccine are now no less important than they were when the bacterium was first identified.

Researchers at the University of Massachusetts Medical School have made a significant breakthrough in the field, modifying Y. pestis with a gene found in another commonly known bacterium, effectively rendering it unable to cause plague. In “Virulence factors of Yersinia pestis are overcome by a strong LPS response,” to be published in the October issue of Nature Immunology, Egil Lien, PhD, assistant professor of medicine and molecular genetics & microbiology, Jon D. Goguen, PhD, associate professor of molecular genetics and microbiology, graduate student Sara Montminy and colleagues, also describe the effectiveness of the modified bacteria as a vaccine.

Innate immunity—the precursor to the adaptive immune system in mammals—acts as the first line of defense against a range of pathogens. Prior to the adaptive immune response that involves the body’s production of antibodies that precisely target and combat the invader, the innate immune system reacts immediately upon infection. Recent research has described an important class of sensor molecules, collectively known as Toll-like receptors (TLRs) that recognize pathogens right away, activating the critical signaling pathways that stimulate this initial immune response. Activation of the TLRs also improves the adaptive immune response; in fact, many vaccines include ingredients known as adjuvants that stimulate the innate immune response.

Intriguingly, the bacteria Y. pestis has an unusual temperature-dependent ability to evade this system. Lipopolysaccharide, or LPS, is a major component of the membrane of this type of bacteria, contributing to structural integrity but also typically provoking a strong response from the immune system. When at human body temperature (37ºC), Y. pestis produces an LPS with a poor ability to activate TLR4, one of the major mammalian innate immunity toll-like receptors; at lower temperatures, for example that of a flea that transmits the disease (26º), the LPS produced was distinctly more potent and thus triggered TLR4.

Recognizing that this difference was not found in E. coli, a common bacterium with some similarities to Y. pestis, Lien identified an E. coli gene that was important for the production of LPS but that was missing in Y. pestis. Using this gene to generate new strains of Y. pestis, researchers produced Y. pestis strains that were recognized much more easily by innate immunity and TLR4 at both temperatures. Importantly, the investigators found that the new strains were unable to cause plague and mortality in normal mice; the strains were at least a million times less virulent than the wild type bacteria.

“Our findings describe one of the secrets of the Black Death,” Lien said. “These results suggest that the production of surface lipids with poor ability to activate innate immunity is essential for Y. pestis to be so deadly, and, in fact, for the ability of the bacteria to cause plague. We expect this strategy to also be important for various other human bacterial pathogens.”

“This result is quite surprising, in part because plague research has focused on many active things that the bacteria do to protect themselves from host defenses, including injecting toxins directly into cells of the immune system that try to engulf them," notes Goguen. “Apparently all of this is useless unless the bugs can also hide from TLR4. Stealth is important.”

Significantly, Lien and colleagues also determined that these new harmless strains of Y. pestis could serve as vaccines. After vaccinating mice with the modified strain of Y. pestis, the investigators re-introduced the virulent strain after 30 days and found that all of the animals were protected from developing plague. These findings show that the production of avirulent bacterial strains with enhanced ability to stimulate the immune system could constitute a new general method for generating effective vaccines.

Source: University of Massachusetts Medical School


print this article email this article download pdf blog this article bookmark this article     Stumble it Digg this share on Facebook retweet share on Reddit add to delicious
Rate this story - 4.2 /5 (44 votes)


September 18, 2006 all stories

Comments: 0

4.2 /5 (44 votes)
  • Stumble this up

  • Digg this

  • share this

  • hide
  • Related Stories

  • Bacteria with a built-in thermometer
    created May 20, 2009 | popularity not rated yet | comments 0
  • Symbiotic microbes induce profound genetic changes in their hosts
    created Jul 28, 2008 | popularity not rated yet | comments 0
  • Mimic molecules to protect against plague
    created Jul 04, 2008 | popularity not rated yet | comments 0
  • Scientists look at 'syringe' assembly in plague bacteria
    created Feb 27, 2008 | popularity not rated yet | comments 0
  • Purified bacterial extract sprayed into lungs ramps up innate immune system
    created Dec 03, 2007 | popularity not rated yet | comments 0



  • hide
  • Relevant PhysicsForums posts

  • nesfatin
    created 5 hours ago
  • Obsessive Compulsive Disorder
    created Nov 20, 2009
  • West's zone 2 starling resistor respiratory physiology
    created Nov 18, 2009
  • 50-0-50 rule
    created Nov 18, 2009
  • What is the evidence in support of the anti-vaccine movement?
    created Nov 17, 2009
  • Chemical Burns
    created Nov 16, 2009
  • More from Physics Forums - Medical Sciences

Other News

New cancer target for non-Hodgkin's lymphoma

Medicine & Health / Cancer

created 5 hours ago | popularity 5 / 5 (1) | comments 0

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, ...


Gene mismatch influences success of bone marrow transplants

Medicine & Health / Genetics

created 5 hours ago | popularity not rated yet | comments 0

A commonly inherited gene deletion can increase the likelihood of immune complications following bone marrow transplantation, an international team of researchers reports in the November 22 advance online issue of Nature Ge ...


Surface bacteria maintain skin's healthy balance

Medicine & Health / Research

created 6 hours ago | popularity 5 / 5 (3) | comments 0

On the skin's surface, bacteria are abundant, diverse and constant, but inflammation is undesirable. Research at the University of California, San Diego School of Medicine now shows that the normal bacteria living on the ...


New understanding about mechanism for cell death after stroke leads to possible therapy

Medicine & Health / Research

created 6 hours ago | popularity not rated yet | comments 0

Scientists at the Brain Research Centre, a partnership of the University of British Columbia Faculty of Medicine and Vancouver Coastal Health Research Institute, have uncovered new information about the mechanism by which ...


Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer

Medicine & Health / Cancer

created 5 hours ago | popularity not rated yet | comments 0

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. This breakthrough ...